Several studies suggested an association between the regular use of β2-agonists and asthma deaths. Whether this association represents adverse effects of β -agonist use or is entirely due to disease severity is a matter of ongoing debate. Previous literature indicates that confounding by poor asthma control may explain the apparent deleterious effects of inhaled β2-agonists. Tolerance to nonbronchodilator effects of β2-agonists may account for the increase in reactivity to indirect bronchoconstrictor challenges and explain why some studies have demonstrated enhanced bronchoconstriction in patients with asthma after regular β 2-agonist therapy. Nonetheless, the salmeterol multi-centre asthma research trial (SMART) found more asthma deaths (13 vs 3) and life-threatening asthma events (37 vs 22) in the salmeterol-treated asthmatic patients, although it was documented that among African-Americans, 5 times as many deaths and near-deaths from asthma occurred in those given salmeterol than in those given placebo, and among patients with asthma not using an inhaled corticosteroid (ICS) as a preventive (controller) medication, again more deaths and near-deaths from asthma occurred in those given salmeterol than in those given placebo. Only 38% of the African-Americans who participated in the study used an ICS. As a result of the findings from the SMART, FDA issued a public health advisory to highlight that long-acting β2-agonists (LABAs) should not be the first medicine used to treat asthma. LABAs should be added to the asthma treatment plan only if other medicines, including the use of low-or-medium dose ICSs, do not control asthma. However, despite all of the concerns raised by the SMART, inhaled β2-agonists remain the most effective bronchodilators available for the immediate relief of asthma symptoms and, as such, remain an important component of asthma management. Obviously, there are concerns about LABA treatment as monotherapy for asthma. Patients with asthma should be initiated and maintained on sufficiently high doses of ICSs and only patients whose asthma cannot be controlled should receive additional LABAs on a regular basis.
Ameredes, B.T. and Calhoun, W.J. (2005) Modulation of GM-CSF release by enantiomers of ß-agonists in human airway smooth muscle. J Allergy Clin Immunol116: 65—72.
2.
American Lung Association Epidemiology & Statistics Unit Research And Scientific Affairs.Trends in Asthma Morbidity and Mortality. May 2005. Available at: www.lungusa.org (accessed May 29, 2007).
3.
Anonymous (1999) ß2-Agonists . Can Med Assoc J161: s28—31.
4.
Antzelevitch, C. (2002)Sympathetic modulation of the long QT syndrome. Eur Heart J23: 1246—1252.
5.
Asthma in America. A landmark survey. Available at: http://www.asthmainamerica.com (accessed May 29, 2007).
6.
Barnes, P.J. and Chung, K.F. (1992) Questions about inhaled β2-adrenoceptor agonists in asthma. Trends Pharmacol Sci13: 20—23.
7.
Barnes, P.J. (1999) Effect of ß agonists on inflammatory cells. J Allergy Clin Immunol104: 10—17.
8.
Barnes, P.J. (2002) Scientific rationale for inhaled combination therapy with long-acting ß2-agonists and corticosteroids. Eur Respir J19: 182—91.
9.
Barnes, P.J. (2006) Treatment with (R)-albuterol has no advantage over racemic albuterol. Am J Respir Crit Care Med174: 969—972.
10.
Bateman, E.D. et al. (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med170: 836—844.
11.
Beasley, R. (2006) A historical perspective of the New Zealand asthma mortality epidemics. J Allergy Clin Immunol117: 225—228.
12.
Bernstein, I.L. (2002) ß2-agonists: deja vu all over again: the second-generation controversy. Chest122: 763—765.
13.
Boudreaux, E.D. et al. (2003) Acute asthma among adults presenting to the emergency department: the role of race/ethnicity and socioeconomic status . Chest124: 803—812.
14.
Castle, W. et al. (1993) Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ306: 1034—1037.
15.
Cazzola, M. et al. (2005) Ultra long-acting ß2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs14: 775—783.
16.
Chong, L.K. et al. (1995). Functional desensitization of ß agonist responses in human lung mast cells. Am J Respir Cell Mol Biol13: 540—546.
17.
Cockcroft, D.W. et al. (1993) Regular inhaled salbutamol and airway responsiveness to allergen. Lancet342: 833—837.
18.
Cockcroft, D.W. et al. (1995) Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol96: 44—49.
19.
Crane, J. et al. (1989) Prescribed fenoterol and death from asthma in New Zealand 1981—83: a case control study. Lancet1: 917—922.
20.
Currie, G.P. (2006) Why SMART about second-line treatment when first-line treatment is being ignored?Chest130: 929.
21.
Dennis, S.M. et al. (2000) Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Lancet355: 1675—1679.
22.
Drazen, J.M. et al. (1996) Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med355: 841—847.
23.
Eisner, M.D. (2001) Inhaled beta agonists and death from asthma: revisiting the controversy. Am J Respir Crit Care Med163: 1502.
24.
Ellsworth, D.L. et al. (2002) Influence of the ß2-adrenergic receptor Arg16Gly polymorphism on longitudinal changes in obesity from childhood through young adulthood in a biracial cohort: the Bogalusa Heart Study. Int J Obes Relat Metab Disord26: 928—937.
25.
FDA Public Health Advisory.Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). Updated May 15, 2006. Available at: http://www.fda.gov/cder/drug/advisory/LABA.htm (accessed May 24, 2007).
26.
Gibson, P.G. et al. (2005) Long-acting ß2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev4: CD005076.
27.
Global Initiative for Asthma.GINA workshop report, global strategy for asthma management and prevention. Available at: www.ginasthma.com/wr_clean.pdf (accessed October 20, 2006).
28.
Greening, A.P. et al. (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet344: 219—224.
29.
Hasford, J. and Virchow, J.C. (2006) Excess mortality in patients with asthma on long-acting ß2-agonists. Eur Respir J28: 900—902.
30.
Inman, M.D. and O'Byrne, P.M. (1996) The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med153: 65—69.
31.
Israel, E. et al. (2004) Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet364: 1505—1512.
32.
Jackson, C.M. and Lipworth, B. (2004) Benefit-risk assessment of long-acting ß2-agonists in asthma. Drug Saf27: 243—270.
33.
Knobil, K. et al. (2003) Salmeterol multi-center asthma research trial (SMART): results from an interim analysis [abstract]. Chest124 Suppl: 335S.
34.
Lipworth, B.J. et al. (1999) Effects of genetic polymorphism on ex vivo and in vivo function of ß2-adrenoceptors in asthmatic patients. Chest115: 324—328.
35.
Lipworth, B.J. (2007) Long-acting ß2-adrenoceptor agonists: a smart choice for asthma?Trends Pharmacol Sci28: 257—262.
36.
Mann, M. et al. (2003) Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest124: 70—74.
37.
Mann, R.D. et al. (1996) Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol49: 247—250.
38.
Martinez, F.D. (2005) Safety of long-acting ß-agonists — an urgent need to clear the air. N Engl J Med353: 2637—2639.
39.
Moore, R.H. et al. (1998) Long-acting inhaled ß2-agonists in asthma therapy. Chest113: 1095—1108.
40.
National Asthma Education and Prevention Program.Expert panel report 2: guidelines for the diagnosis and management of asthma , July 1997, National Heart,
41.
Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
42.
Nelson, H.S. and Dorinsky, P.M. (2006) Safety of long-acting ß-agonists. Ann Intern Med145: 706.
43.
Nelson, H.S. et al. (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest129: 15—26.
44.
Nelson, H.S. (2006a) Long-acting beta-agonists in adult asthma: evidence that these drugs are safe. Prim Care Respir J15: 271—277.
45.
Nelson, H.S. (2006b) Is there a problem with inhaled long-acting ß-adrenergic agonists?J Allergy Clin Immunol117: 3—16.
46.
O'Byrne, P.M. and Ädelroth E. (2006) ß2 déjà vu. Chest129: 3—5.
47.
O'Byrne, P.M. et al. (2001) Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med164: 1392—1397.
48.
O'Byrne, P.M. et al. (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med2005; 171: 129—136.
49.
Page, C.P. and Morley, J. (1999) Contrasting properties of albuterol stereoisomers . J Allergy Clin Immunol104: S31—41.
50.
Page, C.P. (1993) An explanation of the asthma paradox. Am Rev Respir Dis147: S29—32.
51.
Pauwels, R.A. et al. (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med337: 1405—1411.
52.
Pawar, V. and Smith, M.J. (2006) Asthma-related healthcare services utilization by African-Americans enrolled in West Virginia Medicaid. Respir Med100: 1579—1587.
53.
Pearce, N. and Hensley, M.J. (1998) Epidemiologic studies of beta agonists and asthma deaths. Epidemiol Rev20: 173—186.
54.
Pearce, N.E. et al. (2000) Epidemiology of asthma mortality. In Holgate S and Busse W (ed), Asthma and rhinitis, Oxford : Blackwell Scientific, pp. 56—72.
55.
Salpeter, S.R. et al. (2006) Meta-analysis: effect of long-acting ß-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med144: 904—912.
56.
Sears, M.R. et al. (1990) Regular inhaled ß-agonist treatment in bronchial asthma. Lancet336: 1391—1396.
57.
Sears, M.R. and Taylor, D.R. (1994) The ß2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf11: 259—283.
58.
Shah, L. et al. (2003) Long acting beta-agonists versus theophylline for maintenance treatment of asthma. The Cochrane Library, Issue 3. Oxford, UK: Update Software.
59.
Spitzer, W.O. et al. (1992) The use of ß agonists and the risk of death and near death from asthma. N Engl J Med326: 501—506.
60.
Suissa, S. et al. (2000) Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med343: 332—336.
61.
Taylor, D.R. et al. (2000) Asthma exacerbations during long term beta agonist use: influence of ß2 adrenoceptor polymorphism. Thorax55: 762—767.
62.
Taylor, D.R. et al. (1998) Asthma control during long term treatment with regular salbutamol and salmeterol. Thorax53: 744—752.
63.
Walters, E.H. et al. (2003a) Inhaled long acting beta agonists for stable chronic asthma. The Cochrane Library, Issue 4. Oxford, UK: Update Software.
64.
Walters, E.H. et al. (2003b) Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma. The Cochrane Library, Issue 3. Oxford, UK: Update Software.
65.
Walters, J.A. et al. (2005) Long-acting ß2-agonists in asthma: an overview of Cochrane systematic reviews. Respir Med99: 384—395.
66.
Wechsler, M.E. et al. (2006) ß-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med173: 519—526.
67.
Williams, C. (2006) Cause of death in the SMART Trial. Chest130: 929—930.
68.
Wolfe, J. et al. (2006) Formoterol, 24 µg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 µg bid, with and without extra doses taken on demand, and placebo. Chest129: 27—38.
69.
Wooltorton, E. (2005) Long-acting ß2-agonists in asthma: safety concerns . CMAJ173: 1030—1031.
